Breast Cancer Treatment and Adverse Cardiac Events: What Are the Molecular Mechanisms?

Publisher： Karger

E-ISSN： 1421-9751|122|4|253-259

ISSN： 0008-6312

Source： Cardiology, Vol.122, Iss.4, 2012-08, pp. : 253-259

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patient-Reported Adverse Events: What Are We Waiting For?

By Weingart Saul N.  

Joint Commission Journal on Quality and Patient Safety, Vol. 37, Iss. 11, 2011-11 ,pp. : 494-494

Joint Commission Resources

Access to resources Recommend Favorite

Cardiotoxicity Related to Long‐Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors

By  

THE BREAST JOURNAL, Vol. 21, Iss. 3, 2015-05 ,pp. : 318-321

John Wiley & Sons Inc

Access to resources Recommend Favorite

RESULTS IN TREATMENT OF CANCER OF THE BREAST

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 1, Iss. 9, 1953-09 ,pp. : 642-647

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adverse events due to change in organization of problem drug users' treatment?

By Buhl Lars   Sælan Henrik   Møller Sørensen Tine  

Scandinavian Journal of Public Health, Vol. 32, Iss. 2, 2004-04 ,pp. : 130-135

Informa Healthcare

Access to resources Recommend Favorite

Xeloda® in the Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 57, Iss. 1, 1999-07 ,pp. : 16-20

Karger

Access to resources Recommend Favorite